Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)

Off #MRK, Corporate News, Health, Health Information, Human Health, Latest News, Life Sciences, Medicine, Merck, Merck Pharmaceutical, NYSE:MRK, Pharmaceuticals, Prescription Medicine News, Science and Health, Science and Research

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. launch of ONTRUZANT (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin. ONTRUZANT is available in both 150 mg single-dose vials and 420 mg multiple-dose vials.

Language:
English

Contact:

Media:
Pamela Eisele
(267) 305-3558
Michael Close
(267) 305-1211
or
Investor:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab) »

About The Author